Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

American Journal of Therapeutics

Volumn 12, Issue 1, 2005, Pages 22-34

  Mayer, Michael D ^a   Khosravan, Reza ^a   Vernillet, Laurent ^a   Wu, Jing Tao ^a   Joseph Ridge, Nancy ^a   Mulford, Darcy J ^a  

^a TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Bioanalytical; Febuxostat; Pharmacodynamic; Pharmacokinetic; TEI 6720; TMX 67; Uric acid

Indexed keywords

DRUG METABOLITE; FEBUXOSTAT; HYPOXANTHINE; URIC ACID; XANTHINE; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; HEADACHE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; REGRESSION ANALYSIS; URIC ACID BLOOD LEVEL;

ADULT; AGED; AREA UNDER CURVE; BLOOD PROTEINS; FEMALE; HALF-LIFE; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; THIAZOLES; URIC ACID; XANTHINE OXIDASE;

EID: 17144396355     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200501000-00005     Document Type: Article

References (20)

1. Dorland's Illustrated Medical Dictionary, 29th ed. Philadelphia: WB Saunders; 2000:765.
2. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the national health and nutrition examination survey III, 1988-1994. Am J Kidney Dis. 2002;40:37-42.
3. Antigout drugs. (Martindale: the complete drug reference -monograph). In: Sweetman S, ed. DrugKnowledge® System (electronic version). Greenwood Village, CO: MCROMEDEX. Available at: http://csi.micromedex. com/dks/data/mt/mtm1000-f.htm Accessed November 17, 2003.
4. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-451.
5. Wortmann RL, Kelley WN. Gout and hyperuricemia. In: Ruddy, ed. Kelley's Textbook of Rheumatology, 6th ed. Philadelphia: WB Saunders; 2001:1339-1352.
6. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278:1848-1855.
7. Zhao L, Takano Y, Horiuchi H. Effect of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase (NP-SIXO), on enzymes in purine and pyrimidine metabolism pathway. Presented at the American College of Rheumatology Annual Scientific Meeting, Orlando, FL, 2003.
8. Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol. 1993;241:183-188.
9. Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol. 1993; 250:455-460.
10. Horiuchi H, Ota M, Kobayashi M, et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol. 1999;104:307-319.
11. Joseph-Ridge N. Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout. Presented at the American College of Rheumatology Annual Scientific Meeting, New Orleans, LA, 2002.
12. Kamatani N, Fujimori S, Hada T, et al. Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemia. Presented at the American College of Rheumatology Annual Scientific Meeting, Orlando, FL, 2003.
13. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004, in press.
14. Biopharmaceutics Coordinating Committee in the Center for Drug Evaluation and Research (CDER). Guidance for industry: bioanalytical method validation. May 2001.
15. Munda R, Schroeder TJ, Pedersen SA, et al. Cyclosporine pharmacokinetics in pancreas transplant recipients. Transplant Proc. 1988;20(suppl 2):487-490.
16. Volans GN. Migraine and drug absorption. Clin Pharmacokinet. 1978;3:313-318.
17. Brand RM, Lof J, Quigley EMM. Transdermal delivery of erythromycin lactobionate-implications for the therapy of gastroparesis. Aliment Pharmacol Ther. 1997;11:589-592.
18. Moriwaki Y, Yamamoto T, Tsutsumi Z, et al. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol. Metabolism. 2002;51:893-895.
19. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effect of furosemide on the plasma concentration and urinary excretion of purine bases, adenosine, and undine. Metabolism. 2000;49:886-889.
20. Seegmiller JE. Xanthine stone formation. Am J Med. 1968; 45:780-783.